ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Fufang Shenhua tablet inhibits renal fibrosis by inhibiting PI3K/AKT

Li, Run; Shi, Chunru; Wei, Cuiting; Wang, Chao; Du, Hongjian; Liu, Ran; Wang, Xu; Hong, Quan*; Chen, Xiangmei*广东药学院
PHYTOMEDICINE2023-7-25DOI: 10.1016/j.phymed.2023.154873
1被引34阅读
引用收藏
分享

摘要

Background: Fufang Shenhua tablet (SHT), a traditional Chinese medicine compound, has been utilized in the clinical management of chronic kidney disease (CKD) for a long time. Nevertheless, the fundamental active constituents and potential mechanism of action remain unclear. Thus, the objective of this study was to investigate the renoprotective effect of SHT on residual renal tissue in CKD model rats and to explore its primary efficacious components and their underlying mechanism. @@@ Methods: After a 12-week period of SHT treatment through gavage in a 5/6 nephrectomized animal model of CKD, we evaluated the body weight, renal function, and renal pathological changes. Furthermore, the expression levels of fibronectin (FN), collagen I (COL-1), alpha-smooth muscle actin (alpha-SMA), and vimentin in renal tissues were assessed. In addition, network pharmacology analysis and molecular docking were utilized to predict the primary active components, potential therapeutic targets, and intervention pathways through which SHT could potentially exert its anti-kidney fibrosis effects. Subsequently, these predictions were validated in renal tissues of rats with CKD and in transforming growth factor beta 1 (TGF-beta 1)-induced HK-2 cells. @@@ Results: SHT significantly improved renal function and reduced renal pathological damage and fibrosis in CKD model rats. Network pharmacological analysis identified 62 active components in SHT, with quercetin ranked first, and 105 protein targets shared by SHT and CKD. Based on the protein-protein interaction network (PPI) and the SHT-CKD-pathway network, AKT1, MYC, IL2, and VEGFA were identified as key targets. Furthermore, GO and KEGG pathway enrichment analyses indicated that the renoprotective effect of SHT on CKD was closely associated with the PI3K/AKT signaling pathway. Molecular docking results demonstrated that the main active components of SHT had a strong binding affinity to the hub genes. During experimental validation, SHT hindered the activity of the PI3K/AKT signaling pathway in the renal tissue of CKD model rats. Furthermore, activation of the PI3K/AKT signaling pathway was correlated with a modified fibrotic phenotype in rats with 5/6 nephrectomy-induced CKD and TGF-beta 1-induced HK-2 cells. Conversely, SHT and quercetin curtailed the activation of the PI3K/AKT signaling pathway and inhibited the formation of renal fibrosis, thus indicating that the PI3K/AKT signaling pathway is the basis of the antifibrotic effects of SHT. Ultimately, administration of the PI3K/AKT agonist 740Y-P counteracted the fibrotic phenotype of TGF-beta 1-induced HK-2 cells induced by SHT. @@@ Conclusions: In this investigation, we employed a fusion of systems pharmacology and in vivo and in vitro experiments to elucidate the mechanism of SHT's antifibrotic properties via obstruction of the PI3K/AKT signaling pathway. Additionally, we surmised that AKT may be the principal target of SHT for the management of CKD and that quercetin may be its efficacious component. We have thus identified SHT as a promising drug for the amelioration of renal fibrosis and the progression of CKD.

学科与关键词

关键词
Fufang Shenhua tabletNetwork pharmacologyMolecular dockingRenal fibrosisPI3K/AKT signaling pathway
相关
加载中…
  • Protective effects of the Bupi Yishen formula on renal fibrosis through PI3K/AKT signaling inhibition
    Liu, Bingran; Deng, Jiankun; Jie, Xina; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*Journal of Ethnopharmacology, 2022, 293: 115242.被引 4
  • Chinese herbal decoction astragalus and angelica exerts its therapeutic effect on renal interstitial fibrosis through the inhibition of MAPK, PI3K-Akt and TNF signaling pathways
    Yuan, Hao; Wu, Xuelian; Wang, Xiaomin; Yuan, Chengfu*Genes & Diseases, 2022, 9(2): 510-521.被引 5
  • Sanqi Qushi Granule Alleviates Proteinuria and Podocyte Damage in NS Rat: A Network Pharmacology Study and in vivo Experimental Validation
    Wang, Lijuan; Liu, Huoliang; Wang, Yi; Hong, XiaoFan; Huang, Xiaoyan; Han, Miaoru; Wang, Dan; Shan, Wenjun; Li, Ping; Gu, Haowen; Liu, Bo*; Bao, Kun*Drug Design Development and Therapy, 2023, 17: 1847-1861.
查看全部 →

发表信息

论文状态
公开发表
期刊
PHYTOMEDICINE
发表日期
2023-07-25
卷期
第 116 卷
页码
154873
DOI
10.1016/j.phymed.2023.154873
语言
GERMAN
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82070741, 8227075]; [32141005]

作者

  • L

    Li, Run (第一作者)

    chinese peoples liberat army gen hosp · guangdong pharmaceut univ

  • S

    Shi, Chunru

    chinese peoples liberat army gen hosp · guangdong pharmaceut univ

查看全部 9 位作者收起作者
  • W

    Wei, Cuiting

    chinese peoples liberat army gen hosp · guangdong pharmaceut univ

  • W

    Wang, Chao

    chinese peoples liberat army gen hosp · guangdong pharmaceut univ

  • D

    Du, Hongjian

    chinese peoples liberat army gen hosp

  • L

    Liu, Ran

    chinese peoples liberat army gen hosp

  • W

    Wang, Xu

    chinese peoples liberat army gen hosp

  • H

    Hong, Quan (通讯)

    chinese peoples liberat army gen hosp

  • C

    Chen, Xiangmei (通讯)

    chinese peoples liberat army gen hosp · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417